# M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/m13a-bioequivalence-for-immediate-release-solid-oral-dosage-forms/3432d6e2-cab4-4cd5-8507-43579051debb

> FDA guidance document: M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms. Issue date: October 30, 2024. Get complete insights and analysis.

---

## Details

- Title: M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-10-30
- Comment Close Date: 2023-04-03
- Last Changed: 2024-11-01
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2023-D-0093">FDA-2023-D-0093</a>

## Related Documents

- [Requests for Reconsideration at the Division Level Under GDUFA](https://www.globalkeysolutions.net/guidances/guidance-document/requests-for-reconsideration-at-the-division-level-under-gdufa/57f559b5-e6c3-492b-91fd-01762f90e676)
- [Providing Over-the-Counter Monograph Submissions in Electronic Format](https://www.globalkeysolutions.net/guidances/guidance-document/providing-over-the-counter-monograph-submissions-in-electronic-format/772bd042-0dda-4d43-a221-6577f1e823b9)
- [Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-the-development-of-oligonucleotide-therapeutics-guidance-for-industry/716f5680-73b2-4cf4-a88d-c5ade3c8aecd)